Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
:VKTX
Total Valuation
Viking Therapeutics has a market cap or net worth of $2.50B. The enterprise value is $3.58B.
Market Cap$2.50B
Enterprise Value$3.58B
Share Statistics
Viking Therapeutics has 112.29M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding112.29M
Owned by Insiders2.77%
Owned by Instutions11.82%
Financial Efficiency
Viking Therapeutics’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -17.12%.
Return on Equity (ROE)-12.49%
Return on Assets (ROA)-12.11%
Return on Invested Capital (ROIC)-17.12%
Return on Capital Employed (ROCE)-17.13%
Revenue Per Employee$0
Profits Per Employee-$3,054,527.778
Employee Count36
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viking Therapeutics is -39.90. Viking Therapeutics’s PEG ratio is -3.63.
PE Ratio-39.90
PS Ratio0.00
PB Ratio4.98
Price to Fair Value4.98
Price to FCF-49.98
Price to Operating Cash Flow-49.98
PEG Ratio-3.63
Income Statement
In the last 12 months, Viking Therapeutics had revenue of $0.00 and earned -$109.96M in profits. Earnings per share was -$1.00.
Revenue$0.00
Gross Profit-$236.00K
Operating Income-$150.92M
Pretax Income-$109.96M
Net Income-$109.96M
EBITDA-150.74M
Earnings Per Share (EPS)-1.00
Cash Flow
In the last 12 months, operating cash flow was -$87.79M and capital expenditures $0.00, giving a free cash flow of -$87.79M billion.
Operating Cash Flow-$87.79M
Free Cash Flow-$87.79M
Free Cash Flow per Share-$0.78
Dividends & Yields
Viking Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-2.00%
Earnings Yield-2.51%
Stock Price Statistics
Beta1.84
52-Week Price Change-66.81%
50-Day Moving Average28.17
200-Day Moving Average48.28
Relative Strength Index (RSI)39.57
Average Volume (3m)4.38M
Important Dates
Viking Therapeutics upcoming earnings date is Apr 23, 2025, After Close.
Last Earnings DateFeb 5, 2025
Next Earnings DateApr 23, 2025
Ex-Dividend Date―
Financial Position
Viking Therapeutics as a current ratio of 33.09, with Debt / Equity ratio of <0.01
Current Ratio33.09
Quick Ratio33.09
Debt to Market Cap<0.01
Net Debt to EBITDA0.17
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Viking Therapeutics has paid $30.72K in taxes.
Income Tax$30.72K
Effective Tax Rate0.00%
Enterprise Valuation
Viking Therapeutics EV to EBITDA ratio is -28.90, with an EV/FCF ratio of -49.69.
EV to Sales0.00
EV to EBITDA-28.90
EV to Free Cash Flow-49.69
EV to Operating Cash Flow-49.69
Balance Sheet
Viking Therapeutics has $902.61M in cash and marketable securities with $1.12M in debt, giving a net cash position of -$901.49M billion.
Cash & Marketable Securities$902.61M
Total Debt$1.12M
Net Cash-$901.49M
Net Cash Per Share-$8.03
Tangible Book Value Per Share$8.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Viking Therapeutics is $94.85, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$94.85
Price Target Upside326.87%
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast
EPS Growth Forecast-10.27%